Paid Clinical Trials and Focus Groups by Category |
|
|
|
Condition: Gallbladder Neoplasms
Intervention: Drug: Somatostatin
Sponsors: Shanghai Jiao Tong University School of Medicine; Xuanwu hospital capital medical university; Beijing friendship hospital affiliate of capital university of medical sciences; Peking University First Hospital; Tianjin Medical University Cancer Institute and Hospital; First affiliated hospital of Dalian medical university; The First Hospital of China Medical University; The first clinical college of harbin medical university; The 2nd affiliated hospital of harbin medical university; Shengjing hospital of china medical university; China-Japan union hospital of jilin university; The people’s hospital of Heilongjiang province; Eastern Hepatobiliary Surgery Hospital; Shanghai Changzheng Hospital; Shandong Provincial Hospital; Qilu hospital of Shandong university; Xijing hospital of The fourth military medical university; Tangdu hospital of The fourth military medical university; Qinghai povince people’s hospital; Qinghai university affiliated hospital; The first affiliated hospital, Chongqing medical university; Daping hospital of the third military medical university; Kungming the first people’s hospital; Lanzhou university second hospital; Xi'an Center Hospital; The first people’s hospital of Guiyang; Southwest hospital of the third military medical university; Xinqiao hospital of the third military medical university; The first affiliated hospital of kunming medical college; The second affliated hospital of kunming medical college
Recruiting - verified October 2009
Condition: Cholangiocarcinoma
Intervention: Drug: Gemcitabine, Capecitabine and Bevacizumab
Sponsors: Roswell Park Cancer Institute; Genentech
Recruiting - verified February 2010
Condition: Carcinoid Syndrome
Intervention: Drug: BIM 23A760
Sponsor: Ipsen
Recruiting - verified February 2010
Condition: Primary Sclerosing Cholangitis
Intervention:
Sponsor: Mayo Clinic
Recruiting - verified February 2010
Conditions: Anal Cancer; Carcinoma of the Appendix; Colorectal Cancer; Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Gastric Cancer; Gastrointestinal Carcinoid Tumor; Liver Cancer; Nausea and Vomiting; Pancreatic Cancer; Peritoneal Cavity Cancer; Small Intestine Cancer
Interventions: Drug: palonosetron hydrochloride; Other: placebo
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified February 2010
Conditions: Extrahepatic Bile Duct Cancer; Gallbladder Cancer
Interventions: Drug: capecitabine; Drug: gemcitabine hydrochloride; Procedure: adjuvant therapy; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Liver Cancer
Interventions: Drug: capecitabine; Drug: gemcitabine hydrochloride; Procedure: quality-of-life assessment
Sponsor: NCIC Clinical Trials Group
Active, not recruiting - verified March 2010
Conditions: Cholangiocarcinoma Cancer; Gallbladder Cancer; Pancreatic Cancer; Ampullary Cancer
Interventions: Drug: Gemcitabine and Docetaxel (Chemotherapy); Radiation: XRT at 5040 or 5400 cGy and 5FU (Radiation and Chemotherapy); Drug: Gemcitabine and Docetaxel (Chemotherapy)
Sponsor: Washington University School of Medicine
Recruiting - verified February 2010
Condition: Cancer
Interventions: Drug: fentanyl sublingual spray; Other: questionnaire administration
Sponsor: Insys Therapeutics Inc
Recruiting - verified October 2008
Condition: Solid Tumors
Interventions: Drug: AMG 706; Drug: AMG 706; Drug: AMG 706
Sponsor: Amgen
Completed - verified February 2010
Conditions: Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Liver Cancer
Interventions: Drug: capecitabine; Other: clinical observation; Procedure: adjuvant therapy
Sponsor: Southampton University Hospitals NHS Trust
Recruiting - verified March 2008
Condition: Cancer
Interventions: Drug: isolated perfusion; Drug: melphalan
Sponsor: National Cancer Institute (NCI)
Recruiting - verified July 2009
Conditions: Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Liver Cancer
Intervention: Drug: bortezomib
Sponsors: Fox Chase Cancer Center; National Cancer Institute (NCI)
Active, not recruiting - verified February 2010
Condition: Cancer
Interventions: Drug: docetaxel; Drug: thalidomide
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Completed - verified February 2010
Conditions: Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Liver Cancer
Intervention: Drug: erlotinib hydrochloride
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Completed - verified May 2004
Condition: Cancer
Interventions: Drug: dexamethasone; Drug: ondansetron; Procedure: quality-of-life assessment
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Conditions: Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Liver Cancer
Intervention: Drug: becatecarin
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Completed - verified February 2010